Drug Toxicity: Risk factors

Neonates and elderly patients have immature or diminished liver and kidney function, reducing their ability to metabolize and eliminate drugs efficiently. This leads to drug accumulation in their bodies, increasing the likelihood of adverse drug reactions. Both populations require careful dose monitoring and adjustment to prevent toxicity.

Females experience a 1.5 to 1.7-fold greater risk of adverse drug reactions than males due to variations in pharmacokinetics, immune responses, and hormonal differences. These physiological differences affect how women absorb, distribute, metabolize, and eliminate drugs, leading to altered drug concentrations and increased toxicity risk.

Taking multiple prescriptions, over-the-counter drugs, or natural products increases drug-drug interactions and toxicity risk. Polypharmacy elevates the complexity of drug regimens, making it difficult to predict how medications will interact. This complexity is particularly dangerous when combined with pre-existing organ dysfunction or prolonged therapy duration.

Comorbid conditions such as congestive heart failure, hepatitis, obesity, malnutrition, and diabetes alter how patients metabolize drugs, leading to increased drug accumulation and toxicity. These conditions impair the liver and kidney function necessary for proper drug elimination, raising the risk of adverse reactions even at standard doses.

Drugs with a narrow therapeutic index, such as anticoagulants and antiepileptics, have a fine line between therapeutic and toxic concentrations. Small variations in dose, metabolism, or drug interactions can push patients into the toxic range. Consistent monitoring ensures drug levels remain within the safe therapeutic window and prevents dose dependent reactions drug toxicology complications.

Pharmacogenetics examines how genetic variations influence individual responses to medications. Genetic differences in drug-metabolizing enzymes, transporters, and drug targets can cause minimal to severe adverse reactions. For example, 5-10% of the population has CYP2D6 variations affecting antidepressant metabolism, while 59% of drugs in ADR studies are metabolized by enzymes showing genetic variability.

Yes, genetic mutations in genes encoding cardiac ion channels can cause severe complications. For instance, 1-2% of people with these mutations who receive antiarrhythmics may develop long-QT syndrome, a potentially fatal cardiac condition leading to cardiac arrest. This demonstrates how pharmacogenetic differences create unpredictable and life-threatening adverse drug reactions.